

**Clinical Trials Adverse Event Reporting Guide,
2017 Edition**

Table of Contents

Introduction	1
What is a Serious Adverse Event? FDA Definitions.....	9
Regulations	13
21 CFR Part 312: Investigational New Drug Application	15
21 CFR 314.80: Postmarketing Reporting of Adverse Drug Experiences.....	59
21 CFR 812: Investigational Device Exemptions.....	97
45 CFR 46: Protection of Human Subjects (“Common Rule”)	119
FDA Guidances	141
Adverse Event Reporting to IRBs — Improving Human Subject Protection	143
Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review.....	153
Establishment and Operation of Clinical Trial Data Monitoring Committees	239
Gene Therapy Clinical Trials – Observing Subjects for Delayed Adverse Events.....	279
Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment	305
Determining the Extent of Safety Data Collection Needed in Late-Stage Premarket and Postapproval Clinical Investigations.....	329
Postmarketing Studies and Clinical Trials – Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act.....	341
Premarketing Risk Assessment.....	363
Safety Assessment for IND Safety Reporting.....	393
Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions	415
Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide	429
ICH Guidances	463
E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.....	465
E2F Development Safety Update Report.....	483
E9 Statistical Principles for Clinical Trials.....	523
OHRP Guidances	571
IRB Continuing Review of Research.....	573
Reporting Incidents to OHRP	611
Unanticipated Problems Involving Risks and Adverse Events.....	617

Forms	643
MedWatch Form FDA 3500A.....	645
MedWatch Form FDA 3500A: Mandatory Reporting of Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)	665